The most recent trading session ended with Organon (OGN) standing at $20.18, reflecting a +1.05% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's daily ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

Organon & Co (OGN) stock saw a decline, ending the day at $19.97 which represents a decrease of $-0.58 or -2.82% from the prior close of $20.55. The stock opened at $20.51 and touched a low of $19.42 ...

GC Therapeutics claims it can create off-the-shelf therapies from induced pluripotent stem cells much faster than with current methods by using a simpler process.

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), retaining the price target of ...

Barclays analyst Balaji Prasad maintained a Buy rating on Organon (OGN – Research Report) today and set a price target of $26.00. The ...

NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

Roivant Sciences Ltd. has sold another company, this time offering up Dermavant Sciences Ltd. to Organon & Co. for $1.2 ...

This summary of recent health news includes U.S. Senator Bernie Sanders advocating for cheaper Ozempic, new findings on ...